


PHARMACEUTICAL 2019

JOHNSON & JOHNSON Rank 186 of 363









PHARMACEUTICAL 2019



JOHNSON & JOHNSON Rank 186 of 363

The relative strengths and weaknesses of JOHNSON & JOHNSON are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of JOHNSON & JOHNSON compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points. The greatest weakness of JOHNSON & JOHNSON is the variable Assets, Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 95%, being 58% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	46,033,000
Cost of Goods Sold	0
Intangible Assets	78,064,000
Liabilities, Current	31,230,000
Liabilities, Non-Current	36,273,000
Other Assets	11,822,000
Other Compr. Net Income	-1,791,000
Other Expenses	32,175,000
Other Liabilities	25,699,000
Other Net Income	-794,000
Other Revenues	81,581,000
Property and Equipment	17,035,000
Research and Development	10,775,000
Selling, General and Administrative Expense	22,540,000

Output Variable	Value in 1000 USD
Assets	152,954,000
Liabilities	93,202,000
Expenses	65,490,000
Revenues	81,581,000
Stockholders Equity	59,752,000
Net Income	15,297,000
Comprehensive Net Income	14,401,500
Economic Capital Ratio	95%

